<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320983</url>
  </required_header>
  <id_info>
    <org_study_id>1601C</org_study_id>
    <nct_id>NCT00320983</nct_id>
  </id_info>
  <brief_title>Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer</brief_title>
  <official_title>A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Study of Adjuvant Topotecan and Cisplatin with Concurrent Radiation Therapy for&#xD;
      Advanced Cervical Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Examines the effects of Topotecan and Cisplatin with radiation for advanced cervical cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease progression</measure>
    <time_frame>disease progress or complete remission</time_frame>
  </primary_outcome>
  <enrollment type="Actual">11</enrollment>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Topotecan</description>
    <other_name>Hycamtin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin</description>
    <other_name>Platinol AQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed advanced cervical carcinoma who, following&#xD;
             optional surgical staging, are not deemed to be curable by either surgery or&#xD;
             radiotherapy alone. This includes patients with stages IIB, IIIA, IIIB or IVA and&#xD;
             stages IB or IIA who in addition have one of the following risk factors:&#xD;
&#xD;
               -  Primary tumor &gt; 6 cm&#xD;
&#xD;
               -  Positive pelvic and/or para-aortic lymph nodes (resected or unresected)&#xD;
&#xD;
               -  Positive surgical margins&#xD;
&#xD;
               -  Depth of invasion greater than 50 % and positive capillary-lymphatic space&#xD;
                  involvement&#xD;
&#xD;
               -  Eligible cell types include squamous, adenosquamous and adenocarcinoma of the&#xD;
                  cervix&#xD;
&#xD;
          -  Patients may have measurable disease (defined as lesions which can be measured in at&#xD;
             least two (2) dimensions by physical examination or any medical imaging technique).&#xD;
             Inability to measure disease will not constitute exclusion criteria.&#xD;
&#xD;
          -  Patients with GOG performance status of 0, 1, or 2.&#xD;
&#xD;
          -  Patients will have recovered from the effects of recent surgery and should be free of&#xD;
             clinically significant infection.&#xD;
&#xD;
          -  Patients must have adequate:&#xD;
&#xD;
               -  Bone marrow function: WBC greater than or equal to 3,000 cells/mm3, platelet&#xD;
                  count greater than or equal to 100,000 cells/mm3, and granulocyte count greater&#xD;
                  than or equal to 1,500 cells/mm3.&#xD;
&#xD;
               -  Renal function: Creatinine less than or equal to 2.0 mg/dl.&#xD;
&#xD;
               -  Hepatic function: Bilirubin less than or equal to 1.5 x institutional normal,&#xD;
                  SGOT and alkaline phosphatase less than or equal to 3 x institutional normal.&#xD;
&#xD;
          -  Patients must have signed an approved informed consent.&#xD;
&#xD;
          -  Patients have met the pre-entry requirements specified in Section 7.0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with GOG performance of 3 or 4.&#xD;
&#xD;
          -  Patients with another malignancy, prior or concomitant, other than skin (excluding&#xD;
             melanoma).&#xD;
&#xD;
          -  Patients with septicemia, severe infection, gastrointestinal bleeding, or intestinal&#xD;
             obstruction.&#xD;
&#xD;
          -  Patients with anatomic abnormalities requiring modification of radiation fields&#xD;
             (pelvic kidney, renal transplant, etc.).&#xD;
&#xD;
          -  Patient with recurrent cervical cancer&#xD;
&#xD;
          -  Patients who have received prior pelvic radiation&#xD;
&#xD;
          -  Pregnant women and women of childbearing potential not using an effective form of&#xD;
             contraception.&#xD;
&#xD;
          -  History of thrombus (10/28/02)&#xD;
&#xD;
          -  History of unstable angina or MI within the past six months. Patients with evidence of&#xD;
             abnormal cardiac conduction (e.g. bundle branch block, heart block) are eligible if&#xD;
             their disease has been stable for the past six months. (10/28/02)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harriet Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>May 1, 2006</study_first_submitted>
  <study_first_submitted_qc>May 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <last_update_submitted>January 6, 2010</last_update_submitted>
  <last_update_submitted_qc>January 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Harriet O Smith, MD; Principal Investigator</name_title>
    <organization>University of New Mexico CRTC</organization>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Cervix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

